Loading...
Patients with hemophilia suffer repeated episodes of bleeding into muscles and joints. These hemorrhages can be prevented by the prophylactic administration of clotting-factor concentrates. However, clinical trials are needed to establish optimal dosing regimens.
To compare the effectiveness between two prophylaxis regimens and between on-demand treatment and prophylaxis therapy, investigators conducted an industry-sponsored, open-label, multicenter, randomized trial involving 66 patients with factor VIII (FVIII)-deficiency hemophilia. During a 6-month run-in period, patients received concentrate for bleeding episodes on demand. During a 12-month prophylaxis period, patients received standard doses of concentrate or doses determined by indiv…